ABSTRACT
The conventional approach is optimal cytoreductive surgery (CRS) and adjuvant chemotherapy with platinum-based and taxolbased chemotherapy. CRS with hyperthermic intraperitoneal chemotherapy was conceived as a locoregional intensified combined approach for peritoneal surface malignancies when the peritoneum is the only site of metastasis. The CRS and hyperthermic intra-peritoneal chemotherapy (HIPEC) have also been applied as consolidation treatment by some investigators. CRS and HIPEC could be applied as secondary treatment after partial response or stable disease after primary treatment consisting of upfront incomplete CRS followed by chemotherapy in patients. The consensus statement considered the platinum-resistant recurrent disease the least favorable time point for the employment of CRS and HIPEC, the available literature data are contradictory in this sense. A drug is considered eligible for HIPEC according to its pharmacokinetic profile, tumor chemosensibility, and toxicity. HIPEC is performed intraoperatively under general anesthesia, via a pump that maintains the temperature and circulation of the drug solution.
